"versionIdentifier","instanceType","uuid:ID","id","rationale"
"2","StudyVersion","e841b718-a905-40c5-b99f-3da6b9277bfb","StudyVersion_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
